Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25351782 | 0.93 | ROCK2 (0.48) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL25349809 | 0.87 | ROCK2 (0.55) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL31535157 | 0.87 | ROCK2 (0.55) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL25350232 | 0.87 | HDAC6 (0.57) | HDAC6ROCK2PIM1GSK3BAURKB | |
| SCHEMBL25352268 | 0.86 | HDAC6 (0.42) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL25350410 | 0.86 | HDAC6 (0.45) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL25352281 | 0.86 | ROCK2 (0.43) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL25352665 | 0.85 | HDAC6 (0.43) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL25352513 | 0.85 | HDAC6 (0.43) | HDAC6ROCK2PAK4PIM1GSK3B | |
| SCHEMBL24215834 | 0.83 | HDAC1 (0.48) | HDAC6ROCK2PAK4PIM1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885ROCK2 2366/4885PAK4 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.